Patients With Renal Impairment and Diabetes Undergoing Computed Tomography

Bracco Diagnostics, Inc1 site in 1 country350 target enrollmentJanuary 2006

ConditionsKidney Diseases

DrugsIopamidol 370 mgI/dL

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Kidney Diseases
Sponsor: Bracco Diagnostics, Inc
Enrollment: 350
Locations: 1
Primary Endpoint: Increase in serum creatinine (SCr) at 48-72 hours post dose
Status: Completed
Last Updated: 18 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue (iopamidol) or Visipaque in diabetic patients with moderate to severe chronic renal impairment undergoing clinically indicated contrast enhanced multidetector computed tomography (MDCT). Serum creatinine will be measured before and up to 48-72 hours post dose.

Registry

clinicaltrials.gov

Start Date

January 2006

End Date

April 2007

Last Updated

18 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Bracco Diagnostics, Inc

Eligibility Criteria

Inclusion Criteria

•Referred for contrast enhanced MDCT
•Documented predose eGFR of greater than or equal to 20 and less than 60 mL/min/1.73m2
•Diagnosed as having diabetes mellitus